{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:20:05Z","timestamp":1788373205855,"version":"build-2803163510"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ancillary testing with immunohistochemistry has shown recent promise in the workup of equivocal bladder lesions. We read with interest the recent findings of Alston et al., who assessed the diagnostic utility of alpha-methylacyl-CoA racemase (AMACR) in comparison to cytokeratin 20 (CK20) in evaluation of atypia in challenging flat urothelial lesions in the differential between carcinoma in situ (CIS) and reactive atypia. AMACR was reported to be a somewhat more specific but less sensitive marker for CIS than CK20, though showing weaker intensity. Spurred by their report, with the knowledge that we had consistently and consecutively performed AMACR, CK20, and p53 on flat urothelial lesions challenging enough to reach intradepartmental consensus, we performed a retrospective review. Similarly, we found that AMACR was less sensitive (80%) and more specific (100%) than CK20, with the same caveat of less staining intensity. Additionally, our p53 review identified a significant rate (~\u200927%) of equivocal\/non-informative findings. Taken together, our experience in this consecutive cohort confirms the impression of Alston et al. regarding the utility and challenges of AMACR use, while highlighting challenges with p53, which we plan to use more sparingly prospectively.<\/jats:p>","DOI":"10.1186\/s13000-020-00984-2","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T16:02:48Z","timestamp":1590508968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia"],"prefix":"10.1186","volume":"15","author":[{"given":"Daniel J.","family":"Neal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahul B.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0982-4607","authenticated-orcid":false,"given":"Steven C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"issue":"8","key":"984_CR1","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1097\/PAS.0000000000000240","volume":"38","author":"MB Amin","year":"2014","unstructured":"Amin MB, Trpkov K, Lopez-Beltran A, Grignon D, et al. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38(8):e20\u201334.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"984_CR2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/00000478-200103000-00010","volume":"25","author":"JK McKenney","year":"2001","unstructured":"McKenney JK, Gomez JA, Desai S, Lee MW, Amin MB. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol. 2001;25(3):356\u201362.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"984_CR3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/ajcp\/aqw127","volume":"146","author":"M Hassan","year":"2016","unstructured":"Hassan M, Solanki S, Kassouf W, Kanber Y, Caglar D, Auger M, et al. Impact of implementing the Paris system for reporting urine cytology in the performance of urine cytology: a correlative study of 124 cases. Am J Clin Pathol. 2016;146(3):384\u201390.","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"984_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/ajcp\/aqy170","volume":"151","author":"N Sassa","year":"2019","unstructured":"Sassa N, Iwata H, Kato M, Murase Y, Seko S, Nishikimi T, et al. Diagnostic utility of UroVysion combined with conventional urinary cytology for Urothelial carcinoma of the upper urinary tract. Am J Clin Pathol. 2019;151(5):469\u201378.","journal-title":"Am J Clin Pathol"},{"issue":"12","key":"984_CR5","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1097\/PAS.0000000000000114","volume":"37","author":"M Aron","year":"2013","unstructured":"Aron M, Luthringer DJ, Mckenney JK, Hansel DE, Westfall DE, Parakh R, et al. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20\/CD44s\/p53) and \u03b1-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. Am J Surg Pathol. 2013;37(12):1815\u201323.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"984_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5858\/arpa.2016-0411-OA","volume":"142","author":"JA Arias-Stella 3rd","year":"2018","unstructured":"Arias-Stella JA 3rd, Shah AB, Gupta NS, Williamson SR. CK20 and p53 Immunohistochemical staining patterns in urinary bladder specimens with equivocal Atypia. Arch Pathol Lab Med. 2018;142(1):64\u20139.","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"984_CR7","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1309\/AJCPKUZ69LXZGFEA","volume":"136","author":"S Gunia","year":"2011","unstructured":"Gunia S, Koch S, Hakenberg OW, May M, Kakies C, Erbersdobler A. Different HER2 protein expression profiles aid in the histologic differential diagnosis between Urothelial carcinoma in situ (CIS) and non-CIS conditions (dysplasia and reactive Atypia) of the urinary bladder mucosa. Am J Clin Pathol. 2011 Jan 12;136(6):881\u20138.","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"984_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13000-019-0871-8","volume":"14","author":"ELJ Alston","year":"2019","unstructured":"Alston ELJ, Zynger DL. Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ? Diagn Pathol. 2019;14(1):91.","journal-title":"Diagn Pathol"},{"issue":"3","key":"984_CR9","first-page":"303","volume":"153","author":"YH Chu","year":"2020","unstructured":"Chu YH, Zhong W, Rehrauer W, Pavelec DM, Ong IM, Arjang D, et al. Clinicopathologic characterization of post-renal transplantation BK Polyomavirus-associated Urothelial carcinoma single institutional experience. Am J Clin Pathol. 2020;153(3):303\u201314.","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"984_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00428-005-0129-6","volume":"448","author":"C Langner","year":"2006","unstructured":"Langner C, Rupar G, Leibl S, Hutterer G, Chromecki T, Hoefler G, et al. Alpha-methylacyl-CoA racemase (AMACR\/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression. Virchows Arch. 2006;448(3):325\u201330.","journal-title":"Virchows Arch"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-020-00984-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-020-00984-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-020-00984-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T23:17:56Z","timestamp":1621984676000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-020-00984-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["984"],"URL":"https:\/\/doi.org\/10.1186\/s13000-020-00984-2","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,26]]},"assertion":[{"value":"18 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Virginia Commonwealth University RAMS-IRB under an expedited protocol with waiver of informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}